← Back to headlines
Guggenheim Initiates Coverage of Opus Genetics (IRD) with 'Buy' Rating
Guggenheim has begun its coverage of Opus Genetics (IRD), assigning a 'Buy' rating to the stock and setting a price target of $16, indicating a positive outlook for the company.
10 Jun, 18:22 — 10 Jun, 18:22
Sources
Showing 1 of 1 sources
